Tango Therapeutics Inc

TNGX is exhibiting Stage 3 distribution characteristics, with price below declining 9 and 20 EMAs and a recent bounce into the 20 EMA that has not been decisively rejected. The medium-term bias remains bearish, favoring sell-side engagement on rallies. Short-term conditions are neutral, suggesting deferred execution until resistance at the 20/9 EMA zone is confirmed. The long-term uptrend above the 200 DMA is intact but would be threatened by a breakdown below the 50 SMA.

• ↑92% objective response rate in MTAP-deleted, RAS-mutant pancreatic cancer Phase 1/2 trial
• ↑$1 billion cash as of June 2026 extends funding into late-stage studies
• ↓Q2 net loss of $55.3 million (-$0.37/share) with $0 collaboration revenue